We are a commercial stage biopharmaceutical company dedicated to discovering, developing and commercializing innovative therapeutics that address unmet medical needs across viral infectious diseases, oncology and inflammatory disorders. With a history that can be traced back from 2018, we are founded by a seasoned leadership team with deep expertise in biopharmaceutical R&D and successfully developed our Core Product, sebaloxavir marboxil tablets, a next-generation oral anti influenza drug, which has been approved by NMPA. We are actively broadening the reach of sebaloxavir marboxil through a suspension formulation tailored for the pediatric population and indication expansion into post-exposure prophylaxis.
2018 Hangzhou Zhengxiang, our predecessor, was established to carry out R&D of therapeutics addressing viral infectious diseases, oncology and inflammatory disorders in June.
2019 We initiated the R&D of sebaloxavir marboxil tablets in February.
2020 Our Company was established in May.
2021 We received NMPA approval for the phase 1 clinical trial of sebaloxavir marboxil tablets in September.
2022 We initiated the phase 2 clinical trial of sebaloxavir marboxil tablets in adults with influenza in July.
2023 We entered into an exclusive sales and promotion agreement with Jumpcan Pharmaceutical for sebaloxavir marboxil tablets in August. We received NMPA approval for the phase 3 clinical trial of sebaloxavir marboxil tablets in adolescents (aged 12 to 17) with influenza in August. We completed the phase 3 clinical trial of sebaloxavir marboxil tablets in adults with influenza in October.
2024 The NMPA accepted our NDA for sebaloxavir marboxil tablets in adults with influenza in February. We received NMPA approval for the phase 1 clinical trial of ZX-8177, a major drug candidate, in June.
2025 We received NMPA approval for the phase 3 clinical trial of sebaloxavir marboxil for suspension in children (aged two and older) with influenza in January. The NMPA accepted our NDA for sebaloxavir marboxil tablets in adolescents with influenza in April. We received approval from NMPA for the phase 3 clinical trial of sebaloxavir marboxil tablets for post-exposure prophylaxis in patients (aged five and older) in April. The NMPA approved sebaloxavir marboxil tablets for the treatment of uncomplicated influenza in adults in July. We entered into a license and distribution agreement with Cigalah Medpharm in relation to sebaloxavir marboxil oral formulations, a leading pharmaceutical distributor in the MENA region in July.
Patient-centered, Science-driven, Synergistic teamwork
Co-founder,
Chairman, Executive President
Co-founder,
Chief Scientific Officer
Chief Operating Officer
Senior Vice President, CMC
Senior Vice President, Commercialization
Vice President, Finance
